We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group.
- Authors
Poplin, Elizabeth; Feng, Yang; Berlin, Jordan; Rothenberg, Mace L; Hochster, Howard; Mitchell, Edith; Alberts, Steven; O'Dwyer, Peter; Haller, Daniel; Catalano, Paul; Cella, David; Benson, Al Bowen, 3rd
- Abstract
Single-agent gemcitabine (GEM) is standard treatment of metastatic pancreatic cancer. Fixed-dose rate (FDR) GEM and GEM plus oxaliplatin have shown promise in early clinical trials. E6201 was designed to compare overall survival (OS) of standard weekly GEM 1,000 mg/m(2)/30 minutes versus GEM FDR 1,500 mg/m(2)/150 minutes or GEM 1,000 mg/m(2)/100 minutes/day 1 plus oxaliplatin 100 mg/m(2)/day 2 every 14 days (GEMOX).
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Vol 27, Issue 23, p3778
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2008.20.9007